Assignee
KINNATE BIOPHARMA INC
US·15 granted patents·12 pending applications·52 citations·filing 2019–2023
Top patents by PatentIndex Score
27 records- 0197US10927111B2Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2020·Granted Feb 23, 2021·9 cites·29 claims
- 0296US11407737B2Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted Aug 9, 2022·8 cites·30 claims
- 0396US11098031B1Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2020·Granted Aug 24, 2021·12 cites·30 claims
- 0495US11377431B2Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted Jul 5, 2022·7 cites·30 claims
- 0595US11345681B1Inhibitors of fibroblast growth factor receptor kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted May 31, 2022·4 cites·19 claims
- 0694US11780862B2Inhibitors of MEK kinaseKINNATE BIOPHARMA INC·Filed 2023·Granted Oct 10, 2023·2 cites·27 claims
- 0791US10894788B2Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2019·Granted Jan 19, 2021·5 cites·29 claims
- 0889US11753395B2Inhibitors of MET kinaseKINNATE BIOPHARMA INC·Filed 2022·Granted Sep 12, 2023·1 cites·30 claims
- 0989US11746095B2Inhibtors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2022·Granted Sep 5, 2023·1 cites·10 claims
- 1086US11918587B2Treatment of cancer with a RAF inhibitorKINNATE BIOPHARMA INC·Filed 2023·Granted Mar 5, 2024·2 cites·20 claims
- 1186US11667634B2Inhibitors of RAF kinasesKINNATE BIOPHARMA INC·Filed 2021·Granted Jun 6, 2023·1 cites·8 claims
- 1282US12122800B2Inhibitors of MEK kinaseKINNATE BIOPHARMA INC·Filed 2023·Granted Oct 22, 2024·0 cites·16 claims
- 1373US11814384B2Inhibtors of Raf kinasesKINNATE BIOPHARMA INC·Filed 2023·Granted Nov 14, 2023·0 cites·30 claims
- 1471US2024182467A1Inhibitors of raf kinasesKINNATE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1566US2022340543A1Inhibitors of raf kinasesKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1662US11390618B2Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2020·Granted Jul 19, 2022·0 cites·20 claims
- 1761US2025163063A1Inhibitors of cdk4/6 kinaseKINNATE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1860US2025059170A1Solid state forms of an fgfr inhibitorKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1958US2024208931A1Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereofKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2056US2024327343A1Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochlorideKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2155US2023374015A1Inhibitors of fibroblast growth factor receptor kinasesKINNATE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2255US2025032458A1Treatment of cancer with an fgfr kinase inhibitorKINNATE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 2353US11447493B2Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2019·Granted Sep 20, 2022·0 cites·19 claims
- 2453US2023074545A1Treatment of cancer with cdk12/13 inhibitorsKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 2552US2022388990A1Inhibitors of cyclin-dependent kinasesKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 2651US2023081390A1Inhibitors of raf kinasesKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 2751US2023174535A1Inhibitors of fibroblast growth factor receptor kinasesKINNATE BIOPHARMA INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when KINNATE BIOPHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →